About: Mortality of high‐risk orthopaedic oncology patients during the COVID‐19 pandemic: A prospective cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mortality of high‐risk orthopaedic oncology patients during the COVID‐19 pandemic: A prospective cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Mortality of high‐risk orthopaedic oncology patients during the COVID‐19 pandemic: A prospective cohort study
Creator	Correspondence, Jonathan Evans, Scott Lee, \| Parry, Michael Stevenson, Jonathan Tillman, Roger Adesegun, Frcs Dsc, Jeys Frcs, Abudu Frcs, Morris Guy, \| Stevenson,
Source	Medline; PMC
abstract	BACKGROUND AND OBJECTIVES: Should the threshold for orthopaedic oncology surgery during the coronavirus disease‐2019 (COVID‐19) pandemic be higher, particularly in men aged 70 years and older? This study reports the incidence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) during, respiratory complications and 30‐day mortality during the COVID‐19 pandemic. METHODS: This prospective observational cohort study included 100 consecutive patients. The primary outcome measure was 14‐day symptoms and/or SARS‐CoV‐2 test. The secondary outcome was 30‐day postoperative mortality. RESULTS: A total of 100 patients comprising 35 females and 65 males, with a mean age of 52.4 years (range, 16‐94 years) included 16 males aged greater than 70 years. The 51% of patients were tested during their admission for SARS‐CoV‐2; 5% were diagnosed/developed symptoms of SARS‐CoV‐2 during and until 14 days post‐discharge; four were male and one female, mean age 41.2 years (range, 17‐75 years), all had primary malignant bone or soft‐tissue tumours, four of five had received immunosuppressive therapy pre‐operatively. The 30‐day mortality was 1% overall and 20% in those with SARS‐CoV‐2. The pulmonary complication rate was 3% overall. CONCLUSIONS: With appropriate peri‐operative measures to prevent viral transmission, major surgery for urgent orthopaedic oncology patients can continue during the COVID‐19 pandemic. These results need validating with national data to confirm these conclusions.
has issue date	2020-07-15(xsd:dateTime)
bibo:doi	10.1002/jso.26127
bibo:pmid	32668015
has license	no-cc
sha1sum (hex)	098821ce45f394b0efee95937d7e3dbf53354e85
schema:url	https://doi.org/10.1002/jso.26127
resource representing a document's title	Mortality of high‐risk orthopaedic oncology patients during the COVID‐19 pandemic: A prospective cohort study
has PubMed Central identifier	PMC7405118
has PubMed identifier	32668015
schema:publication	J Surg Oncol
resource representing a document's body	covid:098821ce45f394b0efee95937d7e3dbf53354e85#body_text
is schema:about of	named entity 'surgery' covid:arg/098821ce45f394b0efee95937d7e3dbf53354e85 named entity 'pandemic' named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity '2019' named entity 'SARS-CoV-2' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'SARS-CoV-2' named entity 'comorbidities' named entity 'SARS-CoV-2' named entity 'biopsy' named entity 'United Kingdom' named entity 'virus' named entity 'surgical treatment' named entity 'limb-salvage' named entity 'COVID' named entity 'elective surgery' named entity 'SARS-CoV-2 pandemic' named entity 'Malignant disease' named entity 'adjuvant treatment' named entity 'sarcoma' named entity 'SARS-CoV-2' named entity 'respiratory complications' named entity 'plastic surgical' named entity 'orthopaedic care' named entity 'pulmonary atelectasis' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'Royal College of Surgeons' named entity 'pulmonary embolus' named entity 'radiotherapy' named entity 'mortality rate' named entity 'SARS-CoV-2' named entity 'Ewing's sarcoma' named entity 'self-isolate' named entity 'oncology' named entity 'chondroblastoma' named entity 'risk assessment' named entity 'surgical intervention' named entity 'nosocomial' named entity 'orthopaedics' named entity 'peri-operative' named entity 'dependence level' named entity 'coronavirus' named entity 'oncology' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'respiratory failure' named entity 'oncology' named entity 'pneumonia' named entity 'Ewing's sarcoma' named entity 'radiotherapy' named entity 'footfalls' named entity 'cohort study' named entity 'peri-operative' named entity 'COVID' named entity 'adjuvant chemotherapy' named entity 'soft-tissue' named entity 'oncology' named entity 'adjuvant chemotherapy' named entity 'sarcomas' named entity 'ITU' named entity 'peri-operative' named entity 'adamantinoma' named entity 'COVID-19 pandemic' named entity 'spindle cell sarcoma' named entity 'prosthetic' named entity 'osteosarcoma' named entity 'operating theatres' named entity 'soft-tissue'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software